The FDA has imposed restrictions on bluebird bio’s Skysona gene therapy due to reports of blood cancer cases in patients treated with the ex vivo therapy. Skysona was initially approved by the FDA in 2022 to address neurologic dysfunction in boys with cerebral adrenoleukodystrophy (CALD). However, the FDA’s investigation revealed that around 15% of clinical trial participants developed haematological malignancies after treatment with Skysona, a significantly higher rate than initially observed.
The FDA has updated the therapy’s label to limit its use to patients who do not have a suitable donor for a haematopoietic stem cell transplant (HSCT), which was the standard therapy for CALD prior to Skysona’s approval. Reports of life-threatening conditions such as myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) emerging months to years after Skysona treatment have raised concerns about the therapy’s safety profile. The lentiviral vector used in Skysona can integrate into a patient’s DNA, potentially activating cancer genes.
This restriction by the FDA is expected to impact the revenue potential of bluebird’s Skysona, one of the company’s three gene therapies. bluebird, known for its gene therapy products Zynteglo and Lyfgenia, has faced challenges in establishing a profitable business model. The company was recently acquired by investment groups Carlyle and SK Capital Partners for $29 million and continues to operate under new leadership.
According to SEC filings, bluebird treated a total of 70 patients with its gene therapies in the previous year, with Zynteglo being the most utilized, followed by Lyfgenia and Skysona. The limited patient starts for Skysona indicate the impact of the FDA’s safety concerns on the therapy’s adoption. The gene therapy landscape remains challenging due to reimbursement issues for expensive one-time treatments.
Viral clearance (VC) studies have been crucial for ensuring the safety of biologic drugs since the 1990s. These studies help assess the risk of viral contamination in biologic products, ensuring patient safety and product quality. The recent regulatory actions on gene therapies like Skysona highlight the importance of robust safety evaluations in the development and approval of advanced therapies.
In the rapidly evolving field of gene therapy, safety concerns such as the development of haematological malignancies post-treatment present significant challenges for companies like bluebird bio. It is crucial for companies to prioritize patient safety and conduct thorough risk assessments throughout the drug development process. The FDA’s actions underscore the need for continuous monitoring of gene therapy products to ensure their safety and efficacy in treating rare diseases.
Key Takeaways:
1. The FDA has restricted the use of bluebird’s Skysona gene therapy due to reports of haematological malignancies in treated patients, impacting the company’s revenue potential.
2. Safety concerns, such as the development of blood cancers post-treatment, highlight the importance of robust safety evaluations in gene therapy development.
3. Regulatory actions underscore the need for continuous monitoring and risk assessment of advanced therapies to ensure patient safety and treatment efficacy.
Tags: gene therapy, viral clearance, clinical trials
Read more on pharmaphorum.com